Top Story Today
The $11 Billion Bet on Biotech's Picks and Shovels
Merck KGaA is paying $11.3 billion in cash for Bio-Techne, a Minneapolis company that makes the reagents, proteins, and antibodies every biotech lab depends on daily. The $73-per-share offer sits above most Wall Street price targets and hands frustrated shareholders (some nursing 50% losses over five years) a clean exit. It's the latest move in a consolidation wave where Thermo Fisher, Danaher, and now Merck are racing to control the picks and shovels of drug discovery. About 80% of Bio-Techne's revenue comes from consumables that labs reorder constantly: the razor-and-blades model, applied to science.
Why it matters: This deal accelerates a quiet consolidation war in life science tools, reshaping who controls the essential reagents and instruments behind nearly every drug discovery program on the planet.
Read more →Clinical Breakthroughs
One CRISPR Shot Slashed Hereditary Angioedema Attacks by 87%
A single IV infusion of Intellia's CRISPR therapy permanently edited a liver gene and cut swelling attacks by 87% in a pivotal Phase 3 trial, with 62% of patients going completely attack-free over six months. Long-term data from earlier studies show 96%+ reductions lasting three years. Intellia has already started its rolling FDA application, targeting a U.S. launch in the first half of 2027.
Read more →A Pig Kidney Kept a Man Off Dialysis for 271 Days
eGenesis's 69-gene-edited pig kidney sustained a patient for nine months, setting the longest survival record for pig-to-human kidney xenotransplantation. The FDA has now cleared a formal Phase 1/2/3 trial in roughly 30 more patients. With 94,000 Americans on the kidney waitlist and donor supply actually shrinking, pig organs are graduating from proof-of-concept to genuine clinical program.
Read more →J&J Nails First Positive Trial in a Blood Disease With Zero Approved Treatments
Nipocalimab hit its primary endpoint in warm autoimmune hemolytic anemia, a disease where the immune system destroys its own red blood cells and no FDA-approved therapy exists. Nearly two-thirds of patients on the drug achieved hemoglobin levels of ≥10 g/dL with ≥2 g/dL increase from baseline by Week 24, with fatigue improvement kicking in within two weeks. An FDA decision could come by late 2026.
Read more →Insilico's AI-Designed Lung Drug Actually Improved Lung Function
Rentosertib, a molecule discovered and optimized using artificial intelligence by Insilico Medicine, showed lung function gains in IPF patients whose lungs are only supposed to get worse. The top dose group saw a 98 mL improvement in forced vital capacity while placebo patients declined. It's the strongest clinical evidence yet that AI-driven drug discovery can produce real therapeutic results in humans.
Read more →FDA Approvals & Regulatory Moves
Trodelvy Jumps From Last Resort to First Choice in Deadliest Breast Cancer
The FDA approved Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, both as monotherapy and paired with Merck's Keytruda. The move roughly doubles Trodelvy's addressable patient pool and replaces traditional chemo as the backbone of treatment regardless of PD-L1 status. Analysts see a $3 to $4 billion TNBC market opportunity for Gilead.
Read more →Ibrance Crosses Into HER2-Positive Territory for the First Time
Pfizer's Ibrance became the first CDK4/6 inhibitor approved for HER2-positive breast cancer maintenance, delivering 15 extra months of disease control versus standard care in the PATINA trial. The timing is strategic: with Ibrance's core patent expiring in March 2027, the broader label deepens the drug's entrenchment in clinical practice as generics approach.
Read more →The FDA Just Handed CRISPR Companies a Very Specific Safety Checklist
New draft guidance spells out exactly how gene editing companies must use next-generation sequencing to prove their therapies aren't making unintended DNA changes. The rules hit hardest for traditional CRISPR (which cuts both DNA strands), while base editors and prime editors may face a simpler path on structural variant analysis. Comments are due by July 14.
Read more →Deals, Data & Geopolitics
Pfizer's Once-a-Month GLP-1 Shot Posts Solid (If Not Spectacular) Phase 2b Data
Berobenatide delivered 12.3% placebo-adjusted weight loss on a monthly injection schedule, with notably low dropout rates. Wall Street called it solid but not differentiated enough from weekly rivals like Zepbound. Pfizer's $10 billion bet (via its Metsera acquisition) hinges on whether convenience can trump raw efficacy in a market exceeding $50 billion annually.
Read more →ALZpath Hands Abbott the Keys to an Alzheimer's Blood Test
ALZpath licensed its p-tau217 antibody to Abbott for use on the Alinity analyzer platform, one of the world's largest diagnostic equipment networks. The deal means ALZpath's technology now reaches partners covering roughly 80% of the global diagnostics market. The science works (AUCs above 0.92), but reimbursement remains the bottleneck, with CMS initially proposing just $17 per test.
Read more →The Biosecure Act Hasn't Slowed China's Biotech Giants One Bit
Six months after becoming law, the Biosecure Act's contracting bans won't practically kick in until late 2028 at the earliest. Meanwhile, WuXi AppTec posted $6.2 billion in 2025 revenue and is expanding across Singapore and the Middle East. Congress is now eyeing tougher investment controls, but 79% of U.S. pharma still relies on Chinese CDMOs.
Read more →